The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Gene Expression and Benefit of Chemotherapy in Women With Node-Negative, Estrogen Receptor–Positive Breast Cancer
Abstract
Purpose: The 21-gene recurrence score (RS) assay quantifies the likelihood of distant recurrence in women with estrogen receptor–positive, lymph node–negative breast cancer treated with adjuvant tamoxifen. The relationship between the RS and chemotherapy benefit is not known. Methods: The RS was measured in tumors from the tamoxifen-treated and tamoxifen plus chemotherapy–treated patients in the National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 trial. Cox proportional hazards models were utilized to test for interaction between chemotherapy treatment and the RS. Results: A total of 651 patients were assessable (227 randomly assigned to tamoxifen and 424 randomly assigned to tamoxifen plus chemotherapy). The test for interaction between chemotherapy treatment and RS was statistically significant (P = .038). Patients with high-RS (≥ 31) tumors (ie, high risk of recurrence) had a large benefit from chemotherapy (relative risk, 0.26; 95% CI, 0.13 to 0.53; absolute decrease in 10-year distant recurrence rate: mean, 27.6%; SE, 8.0%). Patients with low-RS (< 18) tumors derived minimal, if any, benefit from chemotherapy treatment (relative risk, 1.31; 95% CI, 0.46 to 3.78; absolute decrease in distant recurrence rate at 10 years: mean, −1.1%; SE, 2.2%). Patients with intermediate-RS tumors did not appear to have a large benefit, but the uncertainty in the estimate can not exclude a clinically important benefit. Conclusion: The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor–positive breast cancer, but also predicts the magnitude of chemotherapy benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Self-citationELSTON, C. W., & ELLIS, I. O. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb00229.x · Cited by 6,175
Genes that mediate breast cancer metastasis to lung
Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., Viale, A., Olshen, A. B., Gerald, W. L., & Massagué, J. (2005) · Nature · doi:10.1038/nature03799 · Cited by 2,922
A multigenic program mediating breast cancer metastasis to bone
Kang, Y., Siegel, P. M., Shu, W., Drobnjak, M., Kakonen, S. M., Cordón-Cardo, C., Guise, T. A., & Massagué, J. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00132-6 · Cited by 2,597
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
(2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.13.979 · Cited by 893
Gene expression profiles of human breast cancer progression
Ma, X.-J., Salunga, R., Tuggle, J. T., Gaudet, J., Enright, E., McQuary, P., Payette, T., Pistone, M., Stecker, K., Zhang, B. M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931261100 · Cited by 887
Cited by
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Radiomics: the bridge between medical imaging and personalized medicine
Lambin, P., Leijenaar, R. T. H., Deist, T. M., Peerlings, J., de Jong, E. E. C., van Timmeren, J., Sanduleanu, S., Larue, R. T. H. M., Even, A. J. G., Jochems, A., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.141 · Cited by 5,688
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
“Previous studies have shown significant correlation between mRNA concentrations and routinely established (IHC based) clinical ER status [17–19].”
BackgroundGoldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thürlimann, B., & Senn, H.-J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr304 · Cited by 3,836
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Giuliano, A. E. (2011) · JAMA · doi:10.1001/jama.2011.90 · Cited by 2,942
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
“However, some reports also suggest that basal, mesenchymal-like cancers are initially more sensitive to neoadjuvant chemotherapy than epithelial luminal tumors (Yauch et al., 2005; Paik et al., 2006; Carey et al., 2007; Liedtke et al., 2008).”
ResultAdjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Self-citationHarris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Carey, L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., & Perou, C. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1109 · Cited by 2,087
Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology
Bera, K., Schalper, K. A., Rimm, D. L., Velcheti, V., & Madabhushi, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0252-y · Cited by 1,698
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Gene-Expression Signatures in Breast Cancer
Sotiriou, C., & Pusztai, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0801289 · Cited by 1,485
Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I.-T., Ravdin, P., Bugarini, R., Baehner, F. L., Davidson, N. E., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70314-6 · Cited by 1,407
Self-citationProspective Validation of a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Perez, E. A., Olson, J. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510764 · Cited by 1,388
Self-citationGoldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp322 · Cited by 1,374
Deconstructing the molecular portraits of breast cancer
Prat, A., & Perou, C. M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,343
Concordance among Gene-Expression–Based Predictors for Breast Cancer
Fan, C., Oh, D. S., Wessels, L., Weigelt, B., Nuyten, D. S. A., Nobel, A. B., van't Veer, L. J., & Perou, C. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052933 · Cited by 1,341
Clinical implications of the intrinsic molecular subtypes of breast cancer
Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M. (2015) · The Breast · doi:10.1016/j.breast.2015.07.008 · Cited by 1,319
Herschkowitz, J. I., Simin, K., Weigman, V. J., Mikaelian, I., Usary, J., Hu, Z., Rasmussen, K. E., Jones, L. P., Assefnia, S., Chandrasekharan, S., et al. (2007) · Genome Biology · doi:10.1186/gb-2007-8-5-r76 · Cited by 1,285
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Breast cancer prognostic classification in the molecular era: the role of histological grade
Rakha, E. A., Reis-Filho, J. S., Baehner, F., Dabbs, D. J., Decker, T., Eusebi, V., Fox, S. B., Ichihara, S., Jacquemier, J., Lakhani, S. R., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2607 · Cited by 1,003
Self-citationde Azambuja, E., Cardoso, F., de Castro, G., Colozza, M., Mano, M. S., Durbecq, V, Sotiriou, C., Larsimont, D., Piccart-Gebhart, M. J., & Paesmans, M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603756 · Cited by 959
Wirapati, P., Sotiriou, C., Kunkel, S., Farmer, P., Pradervand, S., Haibe-Kains, B., Desmedt, C., Ignatiadis, M., Sengstag, T., Schütz, F., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2124 · Cited by 891
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., Lin, N. U., Perez, E. A., Goldstein, L. J., Chia, S. K. L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108873 · Cited by 870
Self-citationMicroRNAs accurately identify cancer tissue origin
Rosenfeld, N., Aharonov, R., Meiri, E., Rosenwald, S., Spector, Y., Zepeniuk, M., Benjamin, H., Shabes, N., Tabak, S., Levy, A., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1392 · Cited by 812
Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Translating RNA sequencing into clinical diagnostics: opportunities and challenges
Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D., & Craig, D. W. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.10 · Cited by 809
NCCN Guidelines Insights: Colon Cancer, Version 2.2018
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Cederquist, L., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Engstrom, P. F., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0021 · Cited by 806
Nielsen, T. O., Parker, J. S., Leung, S., Voduc, D., Ebbert, M., Vickery, T., Davies, S. R., Snider, J., Stijleman, I. J., Reed, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1282 · Cited by 801
Cuzick, J., Dowsett, M., Pineda, S., Wale, C., Salter, J., Quinn, E., Zabaglo, L., Mallon, E., Green, A. R., Ellis, I. O., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.2835 · Cited by 739
Gene expression profiling in breast cancer: classification, prognostication, and prediction
Reis-Filho, J. S., & Pusztai, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61539-0 · Cited by 729
Dowsett, M., Cuzick, J., Wale, C., Forbes, J., Mallon, E. A., Salter, J., Quinn, E., Dunbier, A., Baum, M., Buzdar, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4798 · Cited by 724
Self-citationCysteine cathepsin proteases: regulators of cancer progression and therapeutic response
Olson, O. C., & Joyce, J. A. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4027 · Cited by 699
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., Allison, K. H., Anderson, B., Bailey, J., Burstein, H. J., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0035 · Cited by 664
Genomic and personalized medicine: foundations and applications
Ginsburg, G. S., & Willard, H. F. (2009) · Translational Research · doi:10.1016/j.trsl.2009.09.005 · Cited by 637
Decoding global gene expression programs in liver cancer by noninvasive imaging
Segal, E., Sirlin, C. B., Ooi, C., Adler, A. S., Gollub, J., Chen, X., Chan, B. K., Matcuk, G. R., Barry, C. T., Chang, H. Y., et al. (2007) · Nature Biotechnology · doi:10.1038/nbt1306 · Cited by 629
“For instance, in breast cancer, a 21-gene assay, termed Oncotype Dx, is commercially available to determine prognosis and predict response of primary breast tumors to chemotherap”
MethodMolecular biology in breast cancer: Intrinsic subtypes and signaling pathways
Eroles, P., Bosch, A., Alejandro Pérez-Fidalgo, J., & Lluch, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.005 · Cited by 624
Chronic myeloid leukaemia as a model of disease evolution in human cancer
Melo, J. V., & Barnes, D. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2147 · Cited by 623
Dowsett, M., Sestak, I., Lopez-Knowles, E., Sidhu, K., Dunbier, A. K., Cowens, J. W., Ferree, S., Storhoff, J., Schaper, C., & Cuzick, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.1558 · Cited by 621
Mamounas, E. P., Tang, G., Fisher, B., Paik, S., Shak, S., Costantino, J. P., Watson, D., Geyer, C. E., Wickerham, D. L., & Wolmark, N. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7610 · Cited by 619
Self-citationDevelopment of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
Sparano, J. A., & Paik, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1068 · Cited by 617
Self-citationPrat, A., Cheang, M. C. U., Martín, M., Parker, J. S., Carrasco, E., Caballero, R., Tyldesley, S., Gelmon, K., Bernard, P. S., Nielsen, T. O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.4134 · Cited by 587
Tumor Heterogeneity in Breast Cancer
Turashvili, G., & Brogi, E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00227 · Cited by 561
Overview of Breast Cancer Therapy
Moo, T.-A., Sanford, R., Dang, C., & Morrow, M. (2018) · PET Clinics · doi:10.1016/j.cpet.2018.02.006 · Cited by 551
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Wallden, B., Storhoff, J., Nielsen, T., Dowidar, N., Schaper, C., Ferree, S., Liu, S., Leung, S., Geiss, G., Snider, J., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0129-6 · Cited by 542
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904819 · Cited by 532
Self-citationDuffy, M. J., Harbeck, N., Nap, M., Molina, R., Nicolini, A., Senkus, E., & Cardoso, F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.017 · Cited by 522
Addressing overdiagnosis and overtreatment in cancer: a prescription for change
Esserman, L. J., Thompson, I. M., Reid, B., Nelson, P., Ransohoff, D. F., Welch, H. G., Hwang, S., Berry, D. A., Kinzler, K. W., Black, W. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70598-9 · Cited by 501
Current and emerging biomarkers in breast cancer: prognosis and prediction
Weigel, M. T., & Dowsett, M. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-10-0136 · Cited by 496
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Habel, L. A., Shak, S., Jacobs, M. K., Capra, A., Alexander, C., Pho, M., Baker, J., Walker, M., Watson, D., Hackett, J., et al. (2006) · Breast Cancer Research · doi:10.1186/bcr1412 · Cited by 484
Self-citationWeigelt, B., Baehner, F. L., & Reis‐Filho, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2648 · Cited by 482
Self-citationPrimary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Penault-Llorca, F., Poortmans, P., Thompson, A., Zackrisson, S., & Cardoso, F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt284 · Cited by 479
Luminal breast cancer: from biology to treatment
Ignatiadis, M., & Sotiriou, C. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.124 · Cited by 469
Sotiriou, C., & Piccart, M. J. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2173 · Cited by 461
Li, H., Zhu, Y., Burnside, E. S., Drukker, K., Hoadley, K. A., Fan, C., Conzen, S. D., Whitman, G. J., Sutton, E. J., Net, J. M., et al. (2016) · Radiology · doi:10.1148/radiol.2016152110 · Cited by 461
Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Carter, W. B., Edge, S. B., Erban, J. K., Farrar, W. B., Goldstein, L. J., Gradishar, W. J., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0012 · Cited by 450
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy
Schnitt, S. J. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.33 · Cited by 419
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives
Ades, F., Zardavas, D., Bozovic-Spasojevic, I., Pugliano, L., Fumagalli, D., de Azambuja, E., Viale, G., Sotiriou, C., & Piccart, M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.1870 · Cited by 435
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 424
Eccles, S. A., Aboagye, E. O., Ali, S., Anderson, A. S., Armes, J., Berditchevski, F., Blaydes, J. P., Brennan, K., Brown, N. J., Bryant, H. E., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3493 · Cited by 421
Mandrekar, S. J., & Sargent, D. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3701 · Cited by 404
Gray, R. G., Quirke, P., Handley, K., Lopatin, M., Magill, L., Baehner, F. L., Beaumont, C., Clark-Langone, K. M., Yoshizawa, C. N., Lee, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8732 · Cited by 380
Self-citationProgress in adjuvant chemotherapy for breast cancer: an overview
Anampa, J., Makower, D., & Sparano, J. A. (2015) · BMC Medicine · doi:10.1186/s12916-015-0439-8 · Cited by 373
Goldstein, L. J., Gray, R., Badve, S., Childs, B. H., Yoshizawa, C., Rowley, S., Shak, S., Baehner, F. L., Ravdin, P. M., Davidson, N. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4501 · Cited by 369
Self-citationThe I-SPY 1 TRIAL Investigators, Esserman, L. J., Berry, D. A., Cheang, M. C. U., Yau, C., Perou, C. M., Carey, L., DeMichele, A., Gray, J. W., Conway-Dorsey, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1895-2 · Cited by 362
Wu, S.-G., Zhang, W.-W., Wang, J., Dong, Y., Sun, J.-Y., Chen, Y.-X., & He, Z.-Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00001 · Cited by 359
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
Wang, Z., Li, Y., Ahmad, A., Azmi, A. S., Kong, D., Banerjee, S., & Sarkar, F. H. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.07.001 · Cited by 343
Cronin, M., Sangli, C., Liu, M.-L., Pho, M., Dutta, D., Nguyen, A., Jeong, J., Wu, J., Langone, K. C., & Watson, D. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.076497 · Cited by 343
Self-citationKnezevic, D., Goddard, A. D., Natraj, N., Cherbavaz, D. B., Clark-Langone, K. M., Snable, J., Watson, D., Falzarano, S. M., Magi-Galluzzi, C., Klein, E. A., et al. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-690 · Cited by 339
Self-citationNCCN Guidelines® Insights: Breast Cancer, Version 4.2021: Featured Updates to the NCCN Guidelines
Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0023 · Cited by 337
Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., Kraemer, S., Aktas, B., Kuemmel, S., Reimer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5383 · Cited by 333
Self-citationRadiogenomics: Creating a link between molecular diagnostics and diagnostic imaging
Rutman, A. M., & Kuo, M. D. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2009.01.050 · Cited by 321
Dawson, S.-J., Makretsov, N., Blows, F. M., Driver, K. E., Provenzano, E., Le Quesne, J., Baglietto, L., Severi, G., Giles, G. G., McLean, C. A., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605736 · Cited by 317
Ki-67 as a prognostic marker according to breast cancer molecular subtype
Nahed, A. S., & Shaimaa, M. Y. (2016) · Cancer Biology & Medicine · doi:10.20892/j.issn.2095-3941.2016.0066 · Cited by 317
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Burstein, H. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1307118 · Cited by 316
Lo, S. S., Mumby, P. B., Norton, J., Rychlik, K., Smerage, J., Kash, J., Chew, H. K., Gaynor, E. R., Hayes, D. F., Epstein, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2119 · Cited by 303
Chia, S. K., Bramwell, V. H., Tu, D., Shepherd, L. E., Jiang, S., Vickery, T., Mardis, E., Leung, S., Ung, K., Pritchard, K. I., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0286 · Cited by 302
O'Connell, M. J., Lavery, I., Yothers, G., Paik, S., Clark-Langone, K. M., Lopatin, M., Watson, D., Baehner, F. L., Shak, S., Baker, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9538 · Cited by 299
Self-citationPractical implications of gene-expression-based assays for breast oncologists
Prat, A., Ellis, M. J., & Perou, C. M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.178 · Cited by 295
Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer
Symmans, W. F., Hatzis, C., Sotiriou, C., Andre, F., Peintinger, F., Regitnig, P., Daxenbichler, G., Desmedt, C., Domont, J., Marth, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4273 · Cited by 282
Past, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4139 · Cited by 277
Bueno-de-Mesquita, J. M., van Harten, W. H., Retel, V. P., van 't Veer, L. J., van Dam, F. S., Karsenberg, K., Douma, K. F., van Tinteren, H., Peterse, J. L., Wesseling, J., et al. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70346-7 · Cited by 274
The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
Knauer, M., Mook, S., Rutgers, E. J. T., Bender, R. A., Hauptmann, M., van de Vijver, M. J., Koornstra, R. H. T., Bueno-de-Mesquita, J. M., Linn, S. C., & van ’t Veer, L. J. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0814-2 · Cited by 267
Dowsett, M., & Dunbier, A. K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0974 · Cited by 267
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
Zhang, X. H.-F., Giuliano, M., Trivedi, M. V., Schiff, R., & Osborne, C. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0838 · Cited by 264
TAILORx: Trial Assigning Individualized Options for Treatment (Rx)
Sparano, J. A. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.051 · Cited by 262
Future of Personalized Medicine in Oncology: A Systems Biology Approach
Gonzalez-Angulo, A. M., Hennessy, B. T. J., & Mills, G. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0777 · Cited by 261
Benson, J. R., Jatoi, I., Keisch, M., Esteva, F. J., Makris, A., & Jordan, V. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60316-0 · Cited by 261
Commercialized Multigene Predictors of Clinical Outcome for Breast Cancer
Ross, J. S., Hatzis, C., Symmans, W. F., Pusztai, L., & Hortobágyi, G. N. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0248 · Cited by 259
Implementing a Survivorship Care Plan for Patients With Breast Cancer
Ganz, P. A., & Hahn, E. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2851 · Cited by 259
Multigene prognostic tests in breast cancer: past, present, future
Győrffy, B., Hatzis, C., Sanft, T., Hofstatter, E., Aktas, B., & Pusztai, L. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0514-2 · Cited by 257
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Cardoso, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr371 · Cited by 256
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
Febbo, P. G., Ladanyi, M., Aldape, K. D., De Marzo, A. M., Hammond, M. E., Hayes, D. F., Iafrate, A. J., Kelley, R. K., Marcucci, G., Ogino, S., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0137 · Cited by 255
Metadata
- Authors
- Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., Costantino, J. P., Geyer, C. E., Wickerham, D. L., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-08-10
- Volume
- 24
- Issue
- 23
- Pages
- 3726-3734
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2160377567
- Cited by
- 2,579
- References
- 24
- FWCI
- 45.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.